News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

More Human Trials Needed for HIV Vaccine Hunt - September 7, 2010

MedPage Today reported that HIV vaccine researchers are calling for more and better human trials as part of the search for a way to prevent transmission of the virus.  The full story is available here.


Comprehensive New Framework to Speed and Enhance HIV Vaccine Research Released - September 7, 2010

A new comprehensive plan to speed and enhance HIV vaccine research was published in Nature Medicine.

AVAC Calls for Speedy Funding of Critical Microbicide Follow-Up Studies - September 3, 2010

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed.  See below for full announcement.

UNAIDS Statement - Road-map agreed for confirmatory trials of promising microbicide - September 3, 2010

Enterprise-OCTAVE workshop on GPP guidelines wrap-up summary - August 30, 2010

The OCTAVE Project (Online Collaborative Training for AIDS Vaccine Evaluation) and the Global HIV Vaccine Enterprise, in collaboration with AVAC: Global Advocacy for HIV Prevention and UNAIDS, conducted a one-day blended learning workshop in Vienna, Austria, prior to the 2010 International AIDS Society Conference.

Gates Foundation Launches RFP to Diversify Pipeline of Product Concepts for an HIV Vaccine within CAVD - August 25, 2010

The Bill & Melinda Gates Foundation is launching a Request for Proposals (RFP) to address four topic areas in order to diversify the pipeline of product concepts for an HIV vaccine within the Collaboration for AIDS Vaccine Discovery (CAVD) initiative.

Doctors to develop anti-HIV gel for SA - August 17, 2010

Speaking at a media briefing in Cape Town, Dr. Zeda Rosenberg, CEO of the International Partnership for Microbicides, described results of the CAPRISA microbicide trial as a “huge achievement,” but emphasized that the candidate gel needs to be tested again to confirm initial findings.

HIV is a 20th-century disease that needs 21st-century research - August 10, 2010

Alan Bernstein and Peter Piot
The Globe and Mail (Canada)
Tuesday, August 10 2010

We need smarter approaches to clinical trials that test more concepts in less time, for less money, while preserving safety, community engagement and ethical guidelines.

AIDS 2010 Meeting Summary, Vienna - July 30, 2010

The Enterprise hosted and participated in a handful of activities at AIDS 2010.  A summary of the meeting is posted below.

NY Times: Advance on AIDS Raises Questions as Well as Joy - July 27, 2010

The New York Times reported on the CAPRISA 004 results in an article today, “Advance on AIDS Raises Questions as Well as Joy.” The story notes that “after more than a dozen microbicide failures, [the results were] a huge relief, and led to cheering and standing ovations for the researchers.” The story can be found at:

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account